Ireland

--:--IST

Latest

Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide

Subscribe

Registers› Irish medicines ›Ustekinumab

Medicines register · Ireland

Ustekinumab — medicines in Ireland

49 authorised products containing Ustekinumab, from the HPRA register.

Source: HPRA open dataset ("Authorised or Transfer Pending Products"), CC BY 4.0. Complete coverage — all 10,296 authorised products are in this register. Synced 08 Oct 2026, 03:31 UTC

Narrow the register Reset

Search within results

Matches brand name, active substance, licence holder and licence number.

Browse by first letter

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9

Medicine

Active substance

Licence holder

Status

Fymskina 130 mg Concentrate for solution for infusion EU/1/24/1862/003

Ustekinumab

—

Fymskina 45 mg Solution for injection EU/1/24/1862/001

Ustekinumab

—

Fymskina 90 mg Solution for injection EU/1/24/1862/002

Ustekinumab

—

Imuldosa 130 mg Concentrate for solution for infusion EU/1/24/1872/003

Ustekinumab

Accord Healthcare S.L.U.

—

Imuldosa 45 mg Solution for injection EU/1/24/1872/001

Ustekinumab

Accord Healthcare S.L.U.

—

Imuldosa 90 mg Solution for injection EU/1/24/1872/002

Ustekinumab

Accord Healthcare S.L.U.

—

Otulfi 130 mg Concentrate for solution for infusion EU/1/24/1863/003

Ustekinumab

Fresenius Kabi Deutschland GmbH

—

Otulfi 45 mg Solution for injection EU/1/24/1863/001

Ustekinumab

Fresenius Kabi Deutschland GmbH

—

Otulfi 45 mg Solution for injection pre-filled pen EU/1/24/1863/005

Ustekinumab

Fresenius Kabi Deutschland GmbH

—

Otulfi 90 mg Solution for injection EU/1/24/1863/002

Ustekinumab

Fresenius Kabi Deutschland GmbH

—

Otulfi 90 mg Solution for injection in Pre-filled pen EU/1/24/1863/006

Ustekinumab

Fresenius Kabi Deutschland GmbH

—

Pyzchiva 130 mg concentrate for solution for infusion EU/1/24/1801/003

Ustekinumab

Samsung Bioepis NL B.V.

—

Pyzchiva 45 mg solution for injection in pre-filled pen EU/1/24/1801/004

Ustekinumab

Samsung Bioepis NL B.V.

—

Pyzchiva 45 mg solution for injection in pre-filled syringe EU/1/24/1801/001

Ustekinumab

Samsung Bioepis NL B.V.

—

Pyzchiva 90 mg solution for injection in pre-filled pen EU/1/24/1801/005

Ustekinumab

Samsung Bioepis NL B.V.

—

Pyzchiva 90 mg solution for injection in pre-filled syringe EU/1/24/1801/002

Ustekinumab

Samsung Bioepis NL B.V.

—

Qoyvolma 130 mg concentrate for solution for infusion EU/1/25/1925/003

Ustekinumab

Celltrion Healthcare Hungary Kft.

—

Qoyvolma 45 mg solution for injection in pre-filled syringe EU/1/25/1925/001

Ustekinumab

Celltrion Healthcare Hungary Kft.

—

Qoyvolma 90 mg solution for injection in pre-filled syringe EU/1/25/1925/002

Ustekinumab

Celltrion Healthcare Hungary Kft.

—

STELARA 130 mg Concentrate for solution for infusion EU/1/08/494/005

Ustekinumab

Janssen-Cilag International NV

—

STELARA 45 mg Solution for injection EU/1/08/494/003

Ustekinumab

Janssen-Cilag International NV

—

STELARA 45 mg Solution for injection EU/1/08/494/001

Ustekinumab

Janssen-Cilag International NV

—

STELARA 90 mg Solution for injection EU/1/08/494/004

Ustekinumab

Janssen-Cilag International NV

—

STEQEYMA 130 mg Concentrate for solution for infusion EU/1/24/1844/003

Ustekinumab

Celltrion Healthcare Hungary Kft.

—

STEQEYMA 45 mg Solution for injection EU/1/24/1844/001

Ustekinumab

Celltrion Healthcare Hungary Kft.

—

STEQEYMA 90 mg Solution for injection EU/1/24/1844/002

Ustekinumab

Celltrion Healthcare Hungary Kft.

—

Usgena 130 mg concentrate for solution for infusion EU/1/25/1987/005

Ustekinumab

Stada Arzneimittel AG

—

Usgena 45 mg solution for injection EU/1/25/1987/001

Ustekinumab

Stada Arzneimittel AG

—

Usgena 45 mg solution for injection in pre-filled syringe EU/1/25/1987/002

Ustekinumab

Stada Arzneimittel AG

—

Usgena 90 mg solution for injection in pre-filled syringe EU/1/25/1987/003-004

Ustekinumab

Stada Arzneimittel AG

—

Usrenty 130 mg concentrate for solution for infusion EU/1/25/1973/004

Ustekinumab

Biocon Biologics Ireland Limited

—

Usrenty 45 mg solution for injection EU/1/25/1973/001

Ustekinumab

Biocon Biologics Ireland Limited

—

Usrenty 45 mg solution for injection in pre-filled syringe EU/1/25/1973/002

Ustekinumab

Biocon Biologics Ireland Limited

—

Usrenty 90 mg solution for injection in pre-filled syringe EU/1/25/1973/003

Ustekinumab

Biocon Biologics Ireland Limited

—

Usymro 130 mg concentrate for solution for infusion EU/1/25/1957/004

Ustekinumab

Gedeon Richter Plc

—

Usymro 45 mg solution for injection EU/1/25/1957/001

Ustekinumab

Gedeon Richter Plc

—

Usymro 45 mg solution for injection in pre-filled syringe EU/1/25/1957/002

Ustekinumab

Gedeon Richter Plc

—

Usymro 90 mg solution for injection in pre-filled syringe EU/1/25/1957/003

Ustekinumab

Gedeon Richter Plc

—

Uzpruvo 130 mg concentrate for solution for infusion EU/1/23/1784/005

Ustekinumab

Stada Arzneimittel AG

—

Uzpruvo 45 mg solution for injection in pre-filled syringe EU/1/23/1784/001

Ustekinumab

Stada Arzneimittel AG

—

Uzpruvo 90 mg solution for injection in pre-filled syringe EU/1/23/1784/004

Ustekinumab

Stada Arzneimittel AG

—

WEZENLA 130 mg Concentrate for solution for infusion EU/1/24/1823/004

Ustekinumab

Amgen Technology (Ireland) Unlimited Company

—

WEZENLA 45 mg Solution for injection EU/1/24/1823/001

Ustekinumab

Amgen Technology (Ireland) Unlimited Company

—

WEZENLA 45 mg Solution for injection pre-filled syringe EU/1/24/1823/002

Ustekinumab

Amgen Technology (Ireland) Unlimited Company

—

WEZENLA 90 mg Solution for injection pre-filled syringe EU/1/24/1823/003

Ustekinumab

Amgen Technology (Ireland) Unlimited Company

—

Yesintek 130 mg Concentrate for solution for infusion EU/1/24/1892/004

Ustekinumab

Biocon Biologics Ireland Limited

—

Yesintek 45 mg Solution for injection EU/1/24/1892/002

Ustekinumab

Biocon Biologics Ireland Limited

—

Yesintek 45 mg Solution for injection Subcutaneous use EU/1/24/1892/001

Ustekinumab

Biocon Biologics Ireland Limited

—

Yesintek 90 mg Solution for injection EU/1/24/1892/003

Ustekinumab

Biocon Biologics Ireland Limited

—

Cite this view

Priya Life Science (2026). Irish Medicines Register, filtered. Derived from the HPRA open dataset. Retrieved 8 October 2026. https://priyalifescience.com/medicines/substance/ustekinumab

Download this register

GET /api/export.php?register=medicines-ie&format=csv Try the JSON export →

Regulatory information only — not medical advice. For the authoritative record see the HPRA register directly.